SGLT2 inhibitors (SGLT2i) provides nephroprotective benefits in to human patients with DKD, presumably by suppressing HIF1A and stimulating HIF2A, which in turn augments erythropoiesis44–47. This evidence concerns the gene SLC5A2 and diabetic kidney disease.